Department of Urology, Radboud University Medical Centre, Utrecht, The Netherlands.
J Urol. 2012 Oct;188(4):1102-7. doi: 10.1016/j.juro.2012.06.020. Epub 2012 Aug 15.
Survival data on urachal carcinoma are sparse due to the low prevalence of this cancer. We report urachal carcinoma clinical outcomes and prognostic factors in a large, population based cohort of patients with long-term followup.
Data were collected from the nationwide Netherlands Cancer Registry. Urachal carcinoma cases were also cross-referenced using the PALGA (Nationwide Network and Registry of Histology and Cytopathology) database. Pathology report summaries were reviewed. A total of 152 patients diagnosed with urachal carcinoma between 1989 and 2009 were included in analysis. The Sheldon staging system was used to classify urachal carcinoma. Median followup was 9.2 years. Primary outcomes were overall and relative survival. Prognostic factors were calculated using univariate and multivariate hazard regression models.
The incidence of urachal carcinoma was 0.2% of all bladder cancers. A total of 45 patients (30%) presented with lymph node or distant metastasis. Five-year overall and relative survival was 45% and 48%, respectively. On multivariate analysis prognostic factors for impaired survival were lymph node metastasis (HR 1.7, 95% CI 1.2-2.6), tumor growth in the abdominal wall, peritoneum and/or adjacent organs (HR 5.2, 95% CI 2.6-10.3), distant metastasis (HR 5.3, 95% CI 2.8-9.9) and macroscopic residual tumor (HR 5.2, 95% CI 1.2-21.8).
Urachal carcinoma is rare, accounting for 0.2% of all bladder cancers. Many patients present with advanced disease. The prognosis of urachal carcinoma depends mostly on tumor stage, particularly the presence or absence of metastatic disease.
由于这种癌症的发病率较低，因此有关脐尿管癌的生存数据很少。我们报告了在一个大型的、基于人群的患者队列中，对具有长期随访的患者的脐尿管癌临床结果和预后因素。
数据来自全国性的荷兰癌症登记处。还通过 PALGA（全国网络和组织病理学和细胞学登记处）数据库交叉引用脐尿管癌病例。审查了病理报告摘要。共纳入了 1989 年至 2009 年间诊断为脐尿管癌的 152 例患者进行分析。使用 Sheldon 分期系统对脐尿管癌进行分类。中位随访时间为 9.2 年。主要结果是总生存率和相对生存率。使用单变量和多变量风险回归模型计算预后因素。
脐尿管癌的发病率占所有膀胱癌的 0.2%。共有 45 例（30%）患者出现淋巴结或远处转移。5 年总生存率和相对生存率分别为 45%和 48%。多变量分析显示，生存受损的预后因素是淋巴结转移（HR 1.7，95%CI 1.2-2.6）、肿瘤在腹壁、腹膜和/或相邻器官生长（HR 5.2，95%CI 2.6-10.3）、远处转移（HR 5.3，95%CI 2.8-9.9）和大体残留肿瘤（HR 5.2，95%CI 1.2-21.8）。
脐尿管癌罕见，占所有膀胱癌的 0.2%。许多患者出现晚期疾病。脐尿管癌的预后主要取决于肿瘤分期，特别是是否存在转移性疾病。
